Literature DB >> 1260072

"Flooding in vivo" during the circadian phase of minimal cortisol secretion: anxiety and therapeutic success without adrenal cortical activation.

G Curtis, M Buxton, D Lippman, R Nesse, J Wright.   

Abstract

Seven patients with maximally severe phobias for physical objects were treated by "flooding in vivo", i.e. live confrontation with the feared object. Each reported to the laboratory for 3 hr on five separate occasions, all in the early evening during the circadian phase of minimal adrenal cortical activity. At 20-min intervals during each session, blood was taken for cortisol assay, and anxiety was self-rated on a scale of 0 to 100. Treatment was carried out during the 2nd hr of the third and fourth sessions. The remaining time provided control observations. By behavioral and subjective criteria, the treatment hours produced very intense anxiety. However, they failed to evaluate plasma cortisol levels. The remission of the phobias was 100%. Anxiety, even when intense and dramatic, does not necessarily activate the adrenal cortex, and an adrenal "stress" response is not necessary for the therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1260072

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

1.  The psychology of HPA axis activation: Examining subjective emotional distress and control in a phobic fear exposure model.

Authors:  Stefanie E Mayer; Michael Snodgrass; Israel Liberzon; Hedieh Briggs; George C Curtis; James L Abelson
Journal:  Psychoneuroendocrinology       Date:  2017-02-09       Impact factor: 4.905

Review 2.  The neurocircuitry of fear, stress, and anxiety disorders.

Authors:  Lisa M Shin; Israel Liberzon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 3.  An evolutionary medicine perspective on pain and its disorders.

Authors:  Randolph M Nesse; Jay Schulkin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-09-23       Impact factor: 6.237

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.